Table 1.
(a) The results from testing of 40 human chemokines; (b) summary of potential chemokine marker identification.
| (a) | |||
| 6Ckine/CCL21 | Gro-α/CXCL1 | IL-16 | MIP-1α/CCL3 |
| BCA-1/CXCL13 | Gro-β/CXCL2 | IP-10/CXCL10 | MIP-1δ/CCL15 |
| CTACK/CCL27 | I-309/CCL1 | I-TAC/CXCL11 | MIP-3α/CCL20 |
| ENA-78/CXCL5 | IFN-ϒ | MCP-1/CCL2 | MIP-3β/CCL19 |
| Eotaxin/CCL11 | IL-1β | MCP-2/CCL8 | MPIF-1/CCL23 |
| Eotaxin-2/CCL24 | IL-2 | MCP-3/CCL7 | SCYB16/CXCL16 |
| Eotaxin-3/CCL26 | IL-4 | MCP-4/CCL13 | SDF-1α + β/CXCL12 |
| Fractalkine/CX3CL1 | IL-6 | MDC/CCL22 | TARC/CCL17 |
| GCP-2/CXCL6 | IL-8/CXCL8 | MIF | TECK/CCL25 |
| GM-CSF | IL-10 | MIG/CXCL9 | TNF-α |
| (b) | ||||
|---|---|---|---|---|
 Chemokine
|
CC
|
CXC
|
CX3C
|
C
|
| PTSD markers (case–control pre/case post) |
CCL2 CCL15 CCL22 CCL23 CCL25 |
CXCL2 CXCL12 |
None | None |
| Stress markers (control pre/control post) | CCL3 |
CXCL5 CXCL11 CXCL16 |
None | None |
| PTSD risk markers (case–control pre/control pre) |
CCL13 CCL20 CCL23 |
CXCL5 CXCL6 |
None | None |
| Resilience marker (case post/control post) | None | None | CX3CL1 | None |